Cartalax Research Hub

Cartalax is a synthetic short peptide bioregulator belonging to the family of tissue-specific peptides originally developed within the Khavinson peptide research programme. It is classified as an ultra-short synthetic peptide and is commonly described in the literature as the tripeptide Ala-Glu-Asp (AED), although some publications describe a related tetrapeptide variant. The peptide was developed to investigate molecular processes associated with cartilage biology and connective tissue at the cellular level.

Cartalax originated from research into naturally occurring tissue-derived peptide fragments, with subsequent chemical synthesis allowing reproducible laboratory investigation. As with other peptide bioregulators in this class, Cartalax has been studied primarily for its interactions with gene regulatory processes, peptide–cell communication and tissue-specific molecular biology. The published evidence base remains comparatively limited, with much of the available literature originating from the Khavinson research group and related investigations.

Within laboratory settings, Cartalax has been investigated using cultured cell systems, biochemical assays and preclinical experimental models to characterise peptide stability, molecular interactions and cellular regulation. As a synthetic peptide, it is typically manufactured using Solid Phase Peptide Synthesis (SPPS), followed by purification using high-performance liquid chromatography (HPLC). Liquid chromatography–mass spectrometry (LC-MS) is used to confirm peptide identification and molecular mass, and batch-specific Certificates of Analysis (CoAs) record peptide identity, purity, and analytical quality before being made available for use in research.

Rather than being a substance with a well-established mechanism of action, the existing body of evidence mainly supports its usage as an experimental peptide for research of cartilage-associated molecular biology.

The tripeptide sequence Ala-Glu-Asp (AED) makes up Cartalax, a synthetic ultra-short peptide bioregulator. One of the smallest members of the Khavinson peptide family, it is mostly composed of three naturally occurring L-amino acids joined by peptide bonds to form a linear molecule with a molecular weight of roughly 333 Da. Cartalax has a straightforward molecular structure that makes chemical synthesis and analytical characterization easier, in contrast to bigger endogenous proteins or recombinant biologics.

The short amino acid sequence of Cartalax usually exists in aqueous solution as a flexible linear peptide, and its conformation is influenced by environmental factors like pH, ionic strength and solvent composition. The glutamic and aspartic acid residues give the peptide an overall acidic character and a net negative charge at physiological pH.

Current laboratory investigations have examined Cartalax as a synthetic ultra-short peptide bioregulator within the broader family of tissue-specific regulatory peptides. Published experimental studies describe the peptide as being investigated for its interaction with molecular processes involved in cellular regulation, gene expression and protein synthesis. Unlike many peptide hormones or receptor agonists, Cartalax has not been conclusively shown to act through a single, well-defined cell surface receptor, and its molecular mechanism remains an active area of investigation.

In vitro models have explored the interaction of Cartalax with cultured chondrocytes and connective tissue-derived cells to characterise peptide-associated changes in gene transcription and cellular protein expression. Experimental investigations have employed quantitative polymerase chain reaction (qPCR), immunocytochemistry, Western blotting and transcriptomic analyses to examine molecular responses following peptide exposure under controlled laboratory conditions. These studies have focused on characterising regulatory mechanisms rather than establishing physiological outcomes.

Published research has also examined the interaction of Cartalax with chromatin and DNA-associated regulatory processes. Investigations within the peptide bioregulator field have proposed that ultra-short peptides may interact with specific DNA sequences or chromatin-associated proteins, thereby influencing transcriptional activity. These hypotheses have been explored using molecular modelling, DNA-binding studies and gene expression analyses; however, the precise molecular interactions associated specifically with Cartalax continue to be characterised.

Current laboratory investigations have further examined intracellular pathways associated with cellular differentiation, extracellular matrix protein expression and connective tissue biology. Proteomic and transcriptomic approaches have been utilised to investigate peptide-associated changes in regulatory proteins and signalling networks in experimental cell models. While these studies have identified molecular responses following Cartalax exposure, no single intracellular signalling pathway has been established as the primary mechanism of action.

Overall, the published literature characterises Cartalax as an investigational peptide bioregulator whose molecular activity is primarily examined through studies of gene regulation, chromatin biology and tissue-specific cellular signalling. The available evidence remains largely preclinical, and further research is required to define its receptor interactions, molecular targets and intracellular mechanisms with greater precision.

Cartalax is a synthetic ultra-short peptide bioregulator that is typically manufactured using Solid Phase Peptide Synthesis (SPPS), a well-established method for producing short peptide sequences with high sequence fidelity and reproducibility. Following synthesis, the crude peptide undergoes purification, most commonly by preparative high-performance liquid chromatography (HPLC), to remove incomplete peptide sequences, residual coupling reagents and other synthesis-related impurities.

Peptide identification is validated and the expected molecular mass is confirmed using liquid chromatography–mass spectrometry. Analytical HPLC is often used to assess batch-to-batch consistency and analyze peptide purity.

Identity confirmation, purity determination and batch-specific quality testing form part of standard analytical verification procedures before release for research use. The analytical findings are documented within a Certificate of Analysis (CoA).

Cartalax typically comes as a lyophilised peptide. Store it at 2–8°C or according to the manufacturer’s recommended conditions. Keep the material in a dry place and protect it from conditions that may affect its stability during storage. Keep the container securely closed between uses.

For laboratory handling, use clean and dry equipment and avoid unnecessary contact with the material. Minimise exposure to ambient conditions while working with the peptide, and return the container to its recommended storage conditions after handling.